{"id":600214,"date":"2022-05-16T18:54:02","date_gmt":"2022-05-16T18:54:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=600214"},"modified":"2022-05-16T18:54:02","modified_gmt":"2022-05-16T18:54:02","slug":"hepatorenal-syndrome-market-is-expected-to-grow-during-the-forecast-period-20192032-major-companies-mallinckrodt-biovie-cumberland-pharmaceuticals-and-several-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatorenal-syndrome-market-is-expected-to-grow-during-the-forecast-period-20192032-major-companies-mallinckrodt-biovie-cumberland-pharmaceuticals-and-several-others_600214.html","title":{"rendered":"Hepatorenal Syndrome Market is Expected to Grow During the Forecast Period (2019-2032) | Major Companies- Mallinckrodt, BioVie, Cumberland Pharmaceuticals, and Several Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1652678355.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hepatorenal Syndrome Market is Expected to Grow During the Forecast Period (2019-2032) | Major Companies- Mallinckrodt, BioVie, Cumberland Pharmaceuticals, and Several Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1652678355.jpeg\" alt=\"Hepatorenal Syndrome Market is Expected to Grow During the Forecast Period (2019-2032) | Major Companies- Mallinckrodt, BioVie, Cumberland Pharmaceuticals, and Several Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Hepatorenal Syndrome Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Hepatorenal Syndrome Market<\/strong>&#8221; report provides a thorough comprehension of the Hepatorenal Syndrome historical and forecasted epidemiology, and the Hepatorenal Syndrome market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Hepatorenal Syndrome market report also proffers an analysis of the Hepatorenal Syndrome treatment algorithm\/practice, market drivers, market barriers, and unmet medical needs.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hepatorenal syndrome (HRS) is characterized as renal dysfunction secondary to a reduction in renal blood flow (RBF) occurring in the setting of underlying cirrhosis and portal hypertension. It is a severe complication of advanced liver disease and characteristically affects patients with cirrhosis and ascites the pathophysiologic hallmark of HRS is severe vasoconstriction of the renal circulation. Pathogenesis of this vasoconstriction involves a complex interaction between increased portal pressure, changes in the systemic arterial circulation, activation of vasoconstrictor factors and suppression of vasodilator factors acting on the renal circulation.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Free Sample Report Now @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market\"> https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights of the Hepatorenal Syndrome Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to the NORD, Hepatorenal syndrome (HRS) is estimated to occur in approximately 8-10 percent of individuals with the accumulation of fluid in the abdomen (ascites) and cirrhosis.<\/li>\n<li>A study performed by Salerno et al. in Italy included 253 patients with cirrhosis and renal impairment and the estimated occurrence of HRS was in that study was found to be 45.8% (30% type 1 and 15.8% type 2). Moreover, male preponderance was observed in HRS. It is estimated that 76.3% of type 1 HRS and 70% of type 2 HRS patients were males.<\/li>\n<li>The frequency of HRS in fulminant hepatic failure and severe acute alcohol-related hepatitis has been reported to be as high as 55% and 30%, respectively.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Individuals with Hepatorenal Syndrome will have a variety of nonspecific symptoms including fatigue, abdominal pain, malaise, affected individuals may also have symptoms related to advanced liver disease including the ascites, jaundice, splenomegaly, hepatomegaly and others. Hepatorenal Syndrome type I is characterized by a rapid decrease in kidney function and more likely to suffer from hepatic encephalopathy. Hepatorenal syndrome type II causes renal dysfunction that generally progresses much slower than it does in type.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Incident cases<\/li>\n<li>Type-Specific cases<\/li>\n<li>Diagnosed and Treatable cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for More Info @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market\"> https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment of Hepatorenal Syndrome (HRS) includes Liver transplantation as the definitive treatment for HRS, but it is not always possible owing to the short survival expectancy. Nevertheless, liver transplantation should still be done in suitable patients even after the improvement of renal function because the outcome of HRS is poor. Therapies introduced during the past few years, such as vasoconstrictor drugs (vasopressin analogs, &alpha;-adrenergic agonists) or the transjugular intrahepatic portosystemic shunt (TIPS), are effective in improving renal function.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Companies along with therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Terlipressin: Mallinckrodt pharmaceuticals<\/li>\n<li>Ifetroban: Cumberland Pharmaceuticals, and several others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Visit for deep insights into the Hepatorenal Syndrome patient pool @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market\"> https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Several treatment options exist, but, at present, only liver transplantation offers genuine hope for cure and longevity. Challenges for the study of HRS include establishing when renal dysfunction in patients with cirrhosis occurs, largely related to the limitations including the uncertain value of renal biomarkers, and the limited availability of pharmacologic and other therapies to address the fundamental underlying pathophysiology.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hepatorenal Syndrome Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">Although to fulfill the unmet need, much has been learned about the pathophysiology, clinical behavior, and natural history of HRS. Standardized diagnostic criteria have been developed and implemented worldwide, allowing for a more uniform diagnosis and consistent reporting of the disease. One of the most important developments in HRS is the move away from a diagnosis based on a single level of serum Cr to a diagnosis based on dynamic serial changes in serum Cr level such as the recently revised recommendations of the International Ascites Club (IAC) for hepatorenal disorders in cirrhosis. This change has been stimulated by a perceived need to establish more precisely an early diagnosis of the disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Free Sample Report Now @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market\"> https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\">4. Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Hepatorenal Syndrome Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Hepatorenal Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Hepatorenal Syndrome Treatment<\/p>\n<p style=\"text-align: justify;\">11. Hepatorenal Syndrome Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Hepatorenal Syndrome Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Hepatorenal Syndrome: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Hepatorenal Syndrome<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Consult with our business expert @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market\"> https:\/\/www.delveinsight.com\/sample-request\/hepatorenal-syndrome-market<\/a><\/strong>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hepatorenal-syndrome-market-is-expected-to-grow-during-the-forecast-period-20192032-major-companies-mallinckrodt-biovie-cumberland-pharmaceuticals-and-several-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatorenal-syndrome-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hepatorenal-syndrome-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hepatorenal-syndrome-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hepatorenal-syndrome-market-is-expected-to-grow-during-the-forecast-period-20192032-major-companies-mallinckrodt-biovie-cumberland-pharmaceuticals-and-several-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hepatorenal Syndrome Market DelveInsight&#8217;s &#8220;Hepatorenal Syndrome Market&#8221; report provides a thorough comprehension of the Hepatorenal Syndrome historical and forecasted epidemiology, and the Hepatorenal Syndrome market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hepatorenal-syndrome-market-is-expected-to-grow-during-the-forecast-period-20192032-major-companies-mallinckrodt-biovie-cumberland-pharmaceuticals-and-several-others_600214.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,416],"tags":[],"class_list":["post-600214","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/600214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=600214"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/600214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=600214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=600214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=600214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}